This webinar will describe the basic principles of pharmacokinetics, with specific emphasis on issues that can impact toxicokinetics in preclinical safety assessment studies. It will highlight methods for the optimization of physicochemical properties in the discovery and development of oral drug candidates and explore some of the preclinical methods used to select first in human (FIH) doses.
Are you and others in your organization aware of the current best practices in understanding and optimizing pharmacokinetic properties? Poor pharmacokinetics often manifests itself during safety assessment studies, where an inability to achieve acceptable exposures can cause significant program delays and/or terminations of otherwise promising new drug candidates. This webinar will highlight the factors responsible for non-linear dose-exposure relationships that can result in expensive failed safety assessment studies. It will also describe some of the approaches used to achieve acceptable exposures through the use of non-traditional formulation and dosing methods
It is essential that preclinical safety assessment data be interpreted in the context of drug exposures. This webinar describes the principles of pharmacokinetics, such as absorption, distribution, metabolism and excretion (ADME), as well as important concepts such as clearance, the volume of distribution and half-life. It also explores methods used to mitigate issues associated with inferior pharmacokinetic and toxicokinetic profiles, such as poor physicochemical properties--primarily solubility and permeability. Finally, it will highlight some of the in vitro and in vivo preclinical methods used to inform human dose projections.
Areas Covered in the Webinar:From Industries such as Pharma, Biotech, University and Research Institute Drug Discovery Programs
Bryan NormanPresident, Norman Drug Discovery Training and Consulting LLC
Bryan H. Norman received his Ph.D. in Organic Chemistry at Emory University and was an NIH Postdoctoral Fellow at Penn State University. After three years at Monsanto/Searle, Bryan joined Eli Lilly and Company in 1993, where he led multiple cross functional drug discovery efforts, many of which culminated in clinical candidates for oncology, endocrine and pain indications. In addition to his expertise in medicinal chemistry, Bryan has significant cross functional drug discovery experience and expertise in additional disciplines, such as biomarkers, pharmacokinetic/pharmacodynamic (PK/PD) relationships, mechanisms of drug metabolism and toxicology. He has specific expertise in the mechanisms and mitigation strategies to avoid drug-induced liver injury (DILI). The breadth of his background has led to his service on many Due Diligence teams to assess potential in-license opportunities. In addition to drug discovery training and consulting activities, Bryan is currently an Adjunct Professor at the Indiana University School of Medicine, where he teaches multiple drug discovery topics. He is a Volume Editor and serves on the Editorial Board of Burger’s Medicinal Chemistry, Drug Discovery and Development. Bryan is currently on the Board of Directors of the Medicinal and Bioorganic Chemistry Foundation and serves on various grant review committees. He has published over 45 papers in peer-reviewed scientific journals, been named an inventor on over 30 U.S. patents and given many invited lectures at scientific conferences and universities. His most recent research interests have focused on the identification of mechanisms associated with drug-induced liver injury and the discovery of novel analgesic agents for use in chronic pain.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. FDATrainingAlert would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange.
Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.
If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter.
We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email customercare@fdatrainingalert.com call +1-888-771-6965 (Toll Free).
This product hasn't received any reviews yet. Be the first to review this product! Write review
